BioCryst Pharmaceuticals Inc - Asset Resilience Ratio
BioCryst Pharmaceuticals Inc (BCRX) has an Asset Resilience Ratio of 35.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of BioCryst Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how BioCryst Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See BioCryst Pharmaceuticals Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BioCryst Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of BioCryst Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $185.01 Million | 35.98% |
| Total Liquid Assets | $185.01 Million | 35.98% |
Asset Resilience Insights
- Very High Liquidity: BioCryst Pharmaceuticals Inc maintains exceptional liquid asset reserves at 35.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioCryst Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare BioCryst Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for BioCryst Pharmaceuticals Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for BioCryst Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.98% | $185.01 Million | $514.16 Million | -8.09pp |
| 2024-12-31 | 44.07% | $216.14 Million | $490.42 Million | -9.77pp |
| 2023-12-31 | 53.84% | $278.34 Million | $516.96 Million | +32.11pp |
| 2022-12-31 | 21.74% | $119.54 Million | $550.00 Million | +21.19pp |
| 2021-12-31 | 0.55% | $3.21 Million | $588.15 Million | -7.89pp |
| 2020-12-31 | 8.44% | $28.24 Million | $334.71 Million | -4.15pp |
| 2019-12-31 | 12.58% | $22.05 Million | $175.28 Million | -40.36pp |
| 2018-12-31 | 52.94% | $77.74 Million | $146.84 Million | +16.97pp |
| 2017-12-31 | 35.97% | $64.11 Million | $178.26 Million | -0.26pp |
| 2016-12-31 | 36.22% | $32.55 Million | $89.85 Million | +18.03pp |
| 2015-12-31 | 18.20% | $22.66 Million | $124.56 Million | +4.88pp |
| 2014-12-31 | 13.32% | $18.23 Million | $136.87 Million | -21.25pp |
| 2013-12-31 | 34.57% | $16.89 Million | $48.87 Million | +8.96pp |
| 2012-12-31 | 25.61% | $14.71 Million | $57.44 Million | -5.14pp |
| 2011-12-31 | 30.74% | $25.27 Million | $82.21 Million | -5.73pp |
| 2010-12-31 | 36.47% | $40.32 Million | $110.57 Million | +16.89pp |
| 2009-12-31 | 19.58% | $27.84 Million | $142.19 Million | -26.69pp |
| 2008-12-31 | 46.27% | $39.19 Million | $84.69 Million | +32.58pp |
| 2007-12-31 | 13.69% | $19.54 Million | $142.72 Million | -34.55pp |
| 2006-12-31 | 48.24% | $33.04 Million | $68.49 Million | +26.98pp |
| 2005-12-31 | 21.26% | $21.10 Million | $99.25 Million | -22.89pp |
| 2004-12-31 | 44.15% | $14.33 Million | $32.47 Million | +17.28pp |
| 2003-12-31 | 26.87% | $8.09 Million | $30.10 Million | +1.15pp |
| 2002-12-31 | 25.72% | $10.62 Million | $41.30 Million | +3.52pp |
| 2001-12-31 | 22.20% | $13.12 Million | $59.10 Million | -0.64pp |
| 2000-12-31 | 22.84% | $16.18 Million | $70.83 Million | +3.09pp |
| 1999-12-31 | 19.75% | $14.50 Million | $73.40 Million | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more